Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell ...
EurekAlert!

Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. (IMAGE)

Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...